QHSLab (OTCQB:USAQ) and South Dakota State University Celebrate NSF Invitation to Submit STTR Application for AIR-GUIDDE Technology
QHSLab (OTCQB: USAQ) has received an invitation from the National Science Foundation (NSF) to submit a full Phase I application for their AIR-GUIDDE technology development under the NSF Small Business Technology Transfer program. This project, developed in partnership with South Dakota State University, aims to revolutionize drug delivery systems through advanced computational fluid dynamics modeling.
The AIR-GUIDDE platform is designed to provide real-time insights into drug deposition patterns in respiratory and nasal systems, potentially disrupting the $2.6 billion respiratory drug market. The NSF STTR program offers Phase I grants up to $305,000 and Phase II grants up to $1.25 million.
This invitation validates QHSLab's innovative approach and positions the company for significant growth in the digital healthcare solutions market, particularly in drug development and delivery efficiency for conditions such as asthma, COPD, and influenza.
QHSLab (OTCQB: USAQ) ha ricevuto un invito dalla National Science Foundation (NSF) per presentare una domanda completa di Fase I per lo sviluppo della loro tecnologia AIR-GUIDDE nell'ambito del programma NSF Small Business Technology Transfer. Questo progetto, sviluppato in collaborazione con la South Dakota State University, mira a rivoluzionare i sistemi di somministrazione dei farmaci attraverso modelli avanzati di dinamica dei fluidi computazionale.
La piattaforma AIR-GUIDDE è progettata per fornire informazioni in tempo reale sui modelli di deposizione dei farmaci nei sistemi respiratori e nasali, potenzialmente in grado di scuotere il mercato dei farmaci respiratori da 2,6 miliardi di dollari. Il programma STTR della NSF offre sovvenzioni di Fase I fino a 305.000 dollari e sovvenzioni di Fase II fino a 1,25 milioni di dollari.
Questo invito convalida l'approccio innovativo di QHSLab e posiziona l'azienda per una significativa crescita nel mercato delle soluzioni sanitarie digitali, in particolare nello sviluppo e nell'efficienza della consegna dei farmaci per condizioni come asma, BPCO e influenza.
QHSLab (OTCQB: USAQ) ha recibido una invitación de la National Science Foundation (NSF) para presentar una solicitud completa de Fase I para el desarrollo de su tecnología AIR-GUIDDE dentro del programa de Transferencia de Tecnología para Pequeñas Empresas de la NSF. Este proyecto, desarrollado en asociación con la South Dakota State University, tiene como objetivo revolucionar los sistemas de administración de medicamentos mediante la modelización avanzada de dinámica de fluidos computacional.
La plataforma AIR-GUIDDE está diseñada para proporcionar información en tiempo real sobre los patrones de deposición de medicamentos en los sistemas respiratorios y nasales, lo que podría disruptir el mercado de medicamentos respiratorios de 2.6 mil millones de dólares. El programa STTR de la NSF ofrece subvenciones de Fase I de hasta 305,000 dólares y subvenciones de Fase II de hasta 1.25 millones de dólares.
Esta invitación valida el enfoque innovador de QHSLab y posiciona a la empresa para un crecimiento significativo en el mercado de soluciones de salud digital, particularmente en el desarrollo de medicamentos y la eficiencia en la entrega para condiciones como asma, EPOC e influenza.
QHSLab (OTCQB: USAQ)는 National Science Foundation (NSF)로부터 AIR-GUIDDE 기술 개발을 위한 Fase I 전체 신청서를 제출하라는 초청을 받았습니다. 이 프로젝트는 South Dakota State University와의 협력으로 개발되었으며, 고급 계산 유체 역학 모델링을 통해 약물 전달 시스템을 혁신하는 것을 목표로 하고 있습니다.
AIR-GUIDDE 플랫폼은 호흡기 및 비강 시스템에서 약물 침착 패턴에 대한 실시간 통찰력을 제공하도록 설계되어 있으며, 이는 26억 달러 규모의 호흡기 약물 시장을 교란할 가능성이 있습니다. NSF STTR 프로그램은 Fase I 보조금으로 최대 30만 5천 달러, Fase II 보조금으로 최대 125만 달러를 제공합니다.
이 초청은 QHSLab의 혁신적 접근 방식을 검증하며, 특히 천식, COPD 및 독감과 같은 질환의 약물 개발 및 전달 효율성에서 디지털 헬스케어 솔루션 시장의 중요한 성장 기회를 제공합니다.
QHSLab (OTCQB: USAQ) a reçu une invitation de la National Science Foundation (NSF) pour soumettre une demande complète de Phase I pour le développement de leur technologie AIR-GUIDDE dans le cadre du programme de Transfert de Technologie pour Petites Entreprises de la NSF. Ce projet, développé en partenariat avec la South Dakota State University, vise à révolutionner les systèmes de délivrance de médicaments grâce à une modélisation avancée de la dynamique des fluides computationnels.
La plateforme AIR-GUIDDE est conçue pour fournir des informations en temps réel sur les schémas de déposition des médicaments dans les systèmes respiratoires et nasaux, ce qui pourrait perturber le marché des médicaments respiratoires évalué à 2,6 milliards de dollars. Le programme STTR de la NSF propose des subventions de Phase I allant jusqu'à 305 000 dollars et des subventions de Phase II allant jusqu'à 1,25 million de dollars.
Cette invitation valide l'approche innovante de QHSLab et positionne l'entreprise pour une croissance significative sur le marché des solutions de santé numérique, en particulier dans le développement de médicaments et l'efficacité de leur délivrance pour des conditions telles que l'asthme, la BPCO et la grippe.
QHSLab (OTCQB: USAQ) hat eine Einladung von der National Science Foundation (NSF) erhalten, einen vollständigen Antrag für die Phase I zur Entwicklung ihrer AIR-GUIDDE-Technologie im Rahmen des NSF Small Business Technology Transfer-Programms einzureichen. Dieses Projekt wurde in Partnerschaft mit der South Dakota State University entwickelt und zielt darauf ab, die Arzneimittelabgabesysteme durch fortschrittliche Modelle der computergestützten Fluiddynamik zu revolutionieren.
Die AIR-GUIDDE-Plattform ist darauf ausgelegt, Echtzeiteinblicke in die Muster der Arzneimittelabgabe in Atem- und Nasensystemen zu bieten, was potenziell den 2,6 Milliarden Dollar schweren Markt für Atemwegsmedikamente disruptiv beeinflussen könnte. Das NSF STTR-Programm bietet Phase-I-Zuschüsse von bis zu 305.000 Dollar und Phase-II-Zuschüsse von bis zu 1,25 Millionen Dollar.
Diese Einladung validiert den innovativen Ansatz von QHSLab und positioniert das Unternehmen für bedeutendes Wachstum im Markt für digitale Gesundheitslösungen, insbesondere in der Arzneimittelentwicklung und der Effizienz der Arzneimittelabgabe bei Erkrankungen wie Asthma, COPD und Influenza.
- None.
- None.
NSF Recognition: A Testament to Innovation
Driving Strategic Growth and Shareholder Value
WEST PALM BEACH, FL, Dec. 13, 2024 (GLOBE NEWSWIRE) -- QHSLab Inc. ("the Company") (OTCQB: USAQ), a leading provider of digital healthcare solutions and diagnostic technologies, is thrilled to announce that it has been invited by the prestigious National Science Foundation (NSF) to submit a full Phase I application for the development of the Airway Instantaneous Regional Guided Interface for Drug Delivery Efficiency (AIR-GUIDDE). This exclusive invitation, under the NSF Small Business Technology Transfer (STTR) program, underscores the transformative potential of AIR-GUIDDE and highlights the significant merits of the project, even at this early stage.
An Invitation of Distinction
The NSF invitation to submit a full proposal is a key milestone for QHSLab and its partner, South Dakota State University (SDSU). Such invitations are extended only after a rigorous evaluation of the initial Project Pitch, demonstrating the project’s high potential for technical innovation, commercial impact, and societal benefit.
“This invitation from the NSF is a validation of the groundbreaking nature of the AIR-GUIDDE project,” said Saikat Basu, Assistant Professor of Mechanical Engineering at South Dakota State University and Principal Investigator of AIR-GUIDDE. “It reflects not only the advanced scientific principles behind the platform but also its potential to redefine drug delivery in ways that can significantly improve patient outcomes and lower healthcare costs.”
Revolutionizing Drug Development
AIR-GUIDDE is designed to streamline the traditionally expensive and time-consuming process of drug development. By leveraging advanced computational fluid dynamics (CFD) modeling, the platform provides real-time insights into drug deposition patterns in the respiratory and nasal systems. This innovation accelerates development timelines, reduces costs, and increases the precision of drug delivery for conditions such as asthma, COPD, influenza, and pandemic-related viral threats.
Strategic Synergy with QHSLab Technologies
“This partnership and the recognition from NSF exemplify how QHSLab is uniquely positioned to drive innovation and growth,” said Marcos Sanchez-Gonzalez, MD, PhD, Vice President of Medical and Scientific Affairs at QHSLab. “AIR-GUIDDE synergizes perfectly with our existing digital medicine platforms and represents the next step in integrating cutting-edge research with real-world healthcare applications. This is not a departure from our strategy but a reaffirmation of our focus on scalable, revenue-generating innovations that enhance healthcare outcomes.”
Why This Matters for QHSLab and Shareholders
The AIR-GUIDDE project strengthens QHSLab’s trajectory as a leader in digital healthcare solutions while reinforcing its core mission. The NSF’s invitation to apply for funding further validates the Company’s expertise and vision, positioning QHSLab for impactful collaborations and expanding its portfolio of revenue-generating technologies.
The NSF STTR program provides significant financial support to groundbreaking projects like AIR-GUIDDE, with Phase I grants of up to
With AIR-GUIDDE’s potential to disrupt the
A Message from QHSLab’s CEO
“This invitation from the NSF is both a validation of our approach and a tremendous opportunity for growth,” said Troy Grogan, CEO of QHSLab. “The AIR-GUIDDE project is a prime example of how QHSLab’s adaptable technology platform can extend its impact into drug development and discovery. This initiative is fully aligned with our mission and growth strategy, showcasing the versatility of our platforms while delivering sustainable revenue opportunities. Importantly, this effort is neither a distraction nor dilutive to our core business—it’s a reflection of our commitment to innovation and a seamless integration of advanced R&D with real-world applications.”
For more information about QHSLab and our healthcare solutions, please visit www.qhslab.com.
About QHSLab, Inc.
QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also increasing their revenues.
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Olivia Giamanco
QHSLab, Inc.
(929) 379-6503
ir@usaqcorp.com
https://twitter.com/QHSLabInc
FAQ
What is the potential market impact of QHSLab's (USAQ) AIR-GUIDDE technology?
How much funding could USAQ receive from the NSF STTR program for AIR-GUIDDE?
What medical conditions will USAQ's AIR-GUIDDE technology target?
How does USAQ's AIR-GUIDDE technology improve drug development?
What is the significance of NSF's invitation to USAQ for AIR-GUIDDE?
